Anifrolumab, a relatively recent monoclonal protein, is generating considerable interest within the scientific community as a potential option for various immune-related disorders. This innovative medication targets https://ztndz.com/story28691886/anifrolumab-a-promising-treatment-for-immune-mediated-conditions